BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012;8:634-642. [PMID: 23026947 DOI: 10.1038/nrneph.2012.213] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Wada T, Nangaku M. Novel roles of complement in renal diseases and their therapeutic consequences. Kidney Int. 2013;84:441-450. [PMID: 23615508 DOI: 10.1038/ki.2013.134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
2 Sarkar E, Roberts EG, Wallage MJ, Unsworth DJ, Lock RJ. A simple immunofixation test for induced C3 degradation in disease states (including C3 nephritic factor) and its correlation with kidney biopsy. J Immunol Methods 2014;402:71-5. [PMID: 24239583 DOI: 10.1016/j.jim.2013.10.009] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Appel GB. C3 Glomerulopathy: A New Disease Comes of Age. Mayo Clin Proc 2018;93:968-9. [PMID: 30077212 DOI: 10.1016/j.mayocp.2018.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, Cavero T, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez A, Pérez de José A, Rabasco C, Rodado R, Fernández L, Pérez Gómez V, Ávila AI, Bravo L, Lumbreras J, Allende N, Sanchez de la Nieta MD, Rodríguez E, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, Cano-Megías M, González F, Shabaka A, López-Rubio ME, Fenollosa MÁ, Martín-Penagos L, Da Silva I, Alonso Titos J, Rodríguez de Córdoba S, Goicoechea de Jorge E, Praga M; Spanish Group for the Study of Glomerular Diseases GLOSEN. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clin J Am Soc Nephrol 2020;15:1287-98. [PMID: 32816888 DOI: 10.2215/CJN.15241219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Çaltik Yilmaz A, Aydog Ö, Akyüz SG, Bülbül M, Demircin G, Öner A. The relation between treatment and prognosis of childhood membranoproliferative glomerulonephritis. Ren Fail 2014;36:1221-5. [PMID: 25065413 DOI: 10.3109/0886022X.2014.929843] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Kurts C, Panzer U, Anders HJ, Rees AJ. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol. 2013;13:738-753. [PMID: 24037418 DOI: 10.1038/nri3523] [Cited by in Crossref: 350] [Cited by in F6Publishing: 329] [Article Influence: 38.9] [Reference Citation Analysis]
7 Sutherland LJ, Talreja H. C3-glomerulonephritis in New Zealand - a case series. BMC Nephrol 2020;21:399. [PMID: 32943008 DOI: 10.1186/s12882-020-02056-5] [Reference Citation Analysis]
8 Cohen Tervaert JW. Membranoproliferative glomerulonephritis: the times they are a-changin'. Clin Exp Nephrol 2014;18:1-3. [PMID: 23982809 DOI: 10.1007/s10157-013-0852-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Carr JM, Cabezas-Falcon S, Dubowsky JG, Hulme-Jones J, Gordon DL. Dengue virus and the complement alternative pathway. FEBS Lett 2020;594:2543-55. [PMID: 31943152 DOI: 10.1002/1873-3468.13730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Hiramatsu R, Hoshino J, Suwabe T, Sumida K, Hasegawa E, Yamanouchi M, Hayami N, Sawa N, Takaichi K, Ohashi K. Membranoproliferative glomerulonephritis and circulating cryoglobulins. Clin Exp Nephrol. 2014;18:88-94. [PMID: 23722669 DOI: 10.1007/s10157-013-0810-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
11 Wong EK, Anderson HE, Herbert AP, Challis RC, Brown P, Reis GS, Tellez JO, Strain L, Fluck N, Humphrey A, Macleod A, Richards A, Ahlert D, Santibanez-Koref M, Barlow PN, Marchbank KJ, Harris CL, Goodship TH, Kavanagh D. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol 2014;25:2425-33. [PMID: 24722444 DOI: 10.1681/ASN.2013070732] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
12 Boils CL, Nasr SH, Walker PD, Couser WG, Larsen CP. Update on endocarditis-associated glomerulonephritis. Kidney Int 2015;87:1241-9. [PMID: 25607109 DOI: 10.1038/ki.2014.424] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
13 Brocklebank V, Kumar G, Howie AJ, Chandar J, Milford DV, Craze J, Evans J, Finlay E, Freundlich M, Gale DP, Inward C, Mraz M, Jones C, Wong W, Marks SD, Connolly J, Corner BM, Smith-Jackson K, Walsh PR, Marchbank KJ, Harris CL, Wilson V, Wong EKS, Malina M, Johnson S, Sheerin NS, Kavanagh D. Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int 2020;97:1260-74. [PMID: 32386968 DOI: 10.1016/j.kint.2020.01.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
14 de Lorenzo A, Tallón S, Hernández-sevillano B, de Arriba G. C3 glomerulopathy: A new complement-based entity. Revista Clínica Española (English Edition) 2014;214:266-74. [DOI: 10.1016/j.rceng.2014.01.009] [Reference Citation Analysis]
15 Abreu-Velez AM, Howard MS, Yi H, Florez-Vargas AA. Patients affected by a new variant of endemic pemphigus foliaceus have autoantibodies colocalizing with MYZAP, p0071, desmoplakins 1-2 and ARVCF, causing renal damage. Clin Exp Dermatol 2018;43:692-702. [PMID: 29768670 DOI: 10.1111/ced.13566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 2018;93:977-85. [PMID: 29310824 DOI: 10.1016/j.kint.2017.10.022] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
17 Liebau MC. An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr 2014;2:68. [PMID: 25050320 DOI: 10.3389/fped.2014.00068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
18 Meyers KE, Liapis H, Atta MG. American Society of Nephrology clinical pathological conference. Clin J Am Soc Nephrol 2014;9:818-28. [PMID: 24651072 DOI: 10.2215/CJN.12481213] [Reference Citation Analysis]
19 Tatapudi VS, Montgomery RA. Pharmacologic Complement Inhibition in Clinical Transplantation. Curr Transplant Rep 2017;4:91-100. [PMID: 29214126 DOI: 10.1007/s40472-017-0148-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
20 Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, Walz G, Neumann-Haefelin E. Treating C3 glomerulopathy with eculizumab. BMC Nephrol 2018;19:7. [PMID: 29329521 DOI: 10.1186/s12882-017-0802-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
21 Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Molecular Immunology 2020;128:175-87. [DOI: 10.1016/j.molimm.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Suárez-Álvarez B, Liapis H, Anders HJ. Links between coagulation, inflammation, regeneration, and fibrosis in kidney pathology. Lab Invest 2016;96:378-90. [PMID: 26752746 DOI: 10.1038/labinvest.2015.164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
23 Woo SA, Young Ju H, Hyo Kwon S, Lee JH, Jeong Choi S, Cheol Han D, Duk Hwang S, Hong SY, Jin SY, Gil HW. Reanalysis of membranoproliferative glomerulonephritis patients according to the new classification: a multicenter study. Kidney Res Clin Pract 2014;33:187-91. [PMID: 26885475 DOI: 10.1016/j.krcp.2014.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
24 Cianciolo RE, Mohr FC, Aresu L, Brown CA, James C, Jansen JH, Spangler WL, van der Lugt JJ, Kass PH, Brovida C, Cowgill LD, Heiene R, Polzin DJ, Syme H, Vaden SL, van Dongen AM, Lees GE. World Small Animal Veterinary Association Renal Pathology Initiative: Classification of Glomerular Diseases in Dogs. Vet Pathol 2016;53:113-35. [PMID: 25957358 DOI: 10.1177/0300985815579996] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
25 Bomback AS. Anti-complement therapy for glomerular diseases. Adv Chronic Kidney Dis. 2014;21:152-158. [PMID: 24602464 DOI: 10.1053/j.ackd.2013.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
26 Mohapatra A, Kakde S, Annapandian VM, Valson AT, Duhli N, Korula A, Matthai SM, Pulimood AB, David VG, Alexander S, Jacob S, Varughese S, Basu G, Tamilarasi V, John GT. Spectrum of biopsy proven renal disease in South Asian children: Two decades at a tropical tertiary care centre. Nephrology (Carlton) 2018;23:1013-22. [PMID: 28846194 DOI: 10.1111/nep.13160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Caster DJ, Hobeika L, Klein JB, Powell DW, McLeish KR. Changing the concepts of immune-mediated glomerular diseases through proteomics. Proteomics Clin Appl 2015;9:967-71. [PMID: 25907758 DOI: 10.1002/prca.201400159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
28 Caliskan Y, Torun ES, Tiryaki TO, Oruc A, Ozluk Y, Akgul SU, Temurhan S, Oztop N, Kilicaslan I, Sever MS. Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective? Am J Nephrol 2017;46:96-107. [DOI: 10.1159/000479012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
29 Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017;12:25-52. [PMID: 27959629 DOI: 10.1146/annurev-pathol-012615-044145] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
30 Caliskan Y, Kiryluk K. Novel biomarkers in glomerular disease. Adv Chronic Kidney Dis 2014;21:205-16. [PMID: 24602470 DOI: 10.1053/j.ackd.2013.12.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
31 Yeter HH, Sütiçen E, Korucu B, Helvaci Ö, Özbaş B, Gönül İ, Derici Ü, Arinsoy T, Güz G. Evaluation of Clinical, Laboratory and Treatment Modalities in C3 Glomerulopathy: Single Center Experience. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2019;40:15-23. [PMID: 31605593 DOI: 10.2478/prilozi-2019-0010] [Reference Citation Analysis]
32 Häffner K, Michelfelder S, Pohl M. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression. Pediatr Nephrol 2015;30:1951-9. [DOI: 10.1007/s00467-015-3111-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
33 Bettoni S, Bresin E, Remuzzi G, Noris M, Donadelli R. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. J Biol Chem. 2016;291:8214-8230. [PMID: 26903516 DOI: 10.1074/jbc.m115.693119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
34 Shimizu Y, Wakabayashi K, Hayashi Y, Hara K, Aoyama R, Niimi T, Tomino Y, Wada R, Hata M, Suzuki Y. MPGN Type 3 Associated with Pemphigus Herpetiformis Mimicking PGNMID and Dermatitis Herpetiformis. Case Rep Nephrol Dial 2019;9:15-24. [PMID: 31019928 DOI: 10.1159/000498939] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-60. [PMID: 26221755 DOI: 10.1038/ki.2015.227] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 11.3] [Reference Citation Analysis]
36 Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
37 Daneshgar N, Liang P, Michels CJ, Nester CM, Harshman LA, Dai D. Case Report: Clinical and Pathological Findings of a Recurrent C3 Glomerulopathy With Superimposed Membranoproliferative Glomerulonephritis Pattern and Cryoglobulinemia Associated With COVID-19. Front Pediatr 2022;10:827466. [DOI: 10.3389/fped.2022.827466] [Reference Citation Analysis]
38 Esch KJ, Schaut RG, Lamb IM, Clay G, Morais Lima ÁL, do Nascimento PR, Whitley EM, Jeronimo SM, Sutterwala FS, Haynes JS, Petersen CA. Activation of autophagy and nucleotide-binding domain leucine-rich repeat-containing-like receptor family, pyrin domain-containing 3 inflammasome during Leishmania infantum-associated glomerulonephritis. Am J Pathol 2015;185:2105-17. [PMID: 26079813 DOI: 10.1016/j.ajpath.2015.04.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
39 Espinosa-Figueroa JL, Cano-Megías M, Martínez-Miguel P, Velo-Plaza M. Recurrent postinfectious glomerulonephritis: an unusual evolution compatible with C3 glomerulopathy. BMJ Case Rep 2018;2018:bcr-2017-222979. [PMID: 29477994 DOI: 10.1136/bcr-2017-222979] [Reference Citation Analysis]
40 Baikunje S, Vankalakunti M, Nikith A, Srivatsa A, Alva S, Kamath J. Post-infectious glomerulonephritis with crescents in adults: a retrospective study. Clin Kidney J 2016;9:222-6. [PMID: 26985372 DOI: 10.1093/ckj/sfv147] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Ito N, Ohashi R, Nagata M. C3 glomerulopathy and current dilemmas. Clin Exp Nephrol 2017;21:541-51. [PMID: 27878657 DOI: 10.1007/s10157-016-1358-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
42 De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26:2917-2929. [PMID: 26185203 DOI: 10.1681/asn.2015020184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
43 Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Fukuzawa R, Ogata K, Honda M. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: Frequency, clinical features, and outcome in children: MPGN and C3 glomerulonephritis in children. Nephrology 2015;20:286-92. [DOI: 10.1111/nep.12382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
44 Imamura H, Konomoto T, Tanaka E, Hisano S, Yoshida Y, Fujimura Y, Miyata T, Nunoi H. Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B. Nephrology Dialysis Transplantation 2015;30:862-4. [DOI: 10.1093/ndt/gfv054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
45 Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS. Kidney Transplantation in C3 Glomerulopathy: A Case Series. Am J Kidney Dis 2019;73:316-23. [PMID: 30413277 DOI: 10.1053/j.ajkd.2018.09.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
46 Huzmeli C, Candan F, Seker A, Yildiz E, Terzi H, Kayatas M. C3 mesangial proliferative glomerulonephritis initially presenting with atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2016;10:206. [PMID: 27460033 DOI: 10.1186/s13256-016-0992-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Hirashio S, Satoh A, Arima T, Mandai K, Awaya T, Oshima K, Hara S, Masaki T. Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report. BMC Nephrol 2018;19:108. [PMID: 29724182 DOI: 10.1186/s12882-018-0905-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Gupta N, Wakefield DN, Clapp WL, Garin EH. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Nefrologia 2017;37:78-86. [PMID: 27595516 DOI: 10.1016/j.nefro.2016.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
49 Sanghera P, Ghanta M, Ozay F, Ariyamuthu VK, Tanriover B. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options. Am J Med Sci. 2017;354:533-538. [PMID: 29208248 DOI: 10.1016/j.amjms.2017.03.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
50 Pesce F, Stea ED, Rossini M, Fiorentino M, Piancone F, Infante B, Stallone G, Castellano G, Gesualdo L. Glomerulonephritis in AKI: From Pathogenesis to Therapeutic Intervention. Front Med (Lausanne) 2020;7:582272. [PMID: 33738291 DOI: 10.3389/fmed.2020.582272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Bharati J, Tiewsoh K, Kumar A, Nada R, Rathi M, Gupta KL, Kohli HS, Jha V, Ramachandran R. Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy. Clin Kidney J 2019;12:483-7. [PMID: 31384438 DOI: 10.1093/ckj/sfy127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
52 Takei M, Obana A, Inomata T, Tanaka T, Shiang T, Bae Y, Takemura T, Murakami A. Fundus changes in type III membranoproliferative glomerulonephritis: a case report. BMC Ophthalmol 2018;18:72. [PMID: 29510686 DOI: 10.1186/s12886-018-0738-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G; Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy., Nastasi. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol 2018;29:283-94. [PMID: 29030465 DOI: 10.1681/ASN.2017030258] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 7.6] [Reference Citation Analysis]
54 Zuo C, Zhu Y, Xu G. An update to the pathogenesis for monoclonal gammopathy of renal significance. Ann Hematol 2020;99:703-14. [PMID: 32103323 DOI: 10.1007/s00277-020-03971-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Peh CA. Commentary on the KDIGO Clinical Practice Guideline for Glomerulonephritis. Nephrology 2013;18:483-4. [DOI: 10.1111/nep.12091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
56 Nakano M, Karasawa K, Moriyama T, Uchida K, Nitta K. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Clin Exp Nephrol 2019;23:852-8. [PMID: 30854618 DOI: 10.1007/s10157-019-01716-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 De Souza L, Prunster J, Chan D, Chakera A, Lim WH. Recurrent glomerulonephritis after kidney transplantation: a practical approach. Curr Opin Organ Transplant 2021;26:360-80. [PMID: 34039882 DOI: 10.1097/MOT.0000000000000887] [Reference Citation Analysis]
58 Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, Amoedo M, Pires C. Rituximab use in adult glomerulopathies and its rationale. J Bras Nefrol 2020;42:77-93. [PMID: 31904761 DOI: 10.1590/2175-8239-JBN-2018-0254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
59 Zuo C, Zhu Y, Xu G. An update to the pathogenesis for monoclonal gammopathy of renal significance. Crit Rev Oncol Hematol 2020;149:102926. [PMID: 32199132 DOI: 10.1016/j.critrevonc.2020.102926] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Devuyst O, Knoers NV, Remuzzi G, Schaefer F; Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 2014;383:1844-59. [PMID: 24856029 DOI: 10.1016/S0140-6736(14)60659-0] [Cited by in Crossref: 123] [Cited by in F6Publishing: 63] [Article Influence: 15.4] [Reference Citation Analysis]
61 Anders HJ. Innate versus adaptive immunity in kidney immunopathology. BMC Nephrol 2013;14:138. [PMID: 23835035 DOI: 10.1186/1471-2369-14-138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
62 Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol 2016; 5(4): 308-320 [PMID: 27458560 DOI: 10.5527/wjn.v5.i4.308] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
63 Boils CL. Endocarditis-Associated Glomerulonephritis. In: Satoskar AA, Nadasdy T, editors. Bacterial Infections and the Kidney. Cham: Springer International Publishing; 2017. pp. 87-116. [DOI: 10.1007/978-3-319-52792-5_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
64 Masani N, Jhaveri KD, Fishbane S. Update on membranoproliferative GN. Clin J Am Soc Nephrol. 2014;9:600-608. [PMID: 24408117 DOI: 10.2215/cjn.06410613] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
65 Levy Erez D, Meyers KE, Sullivan KE. C3 nephritic factors: A changing landscape. J Allergy Clin Immunol 2017;140:57-9. [PMID: 28322851 DOI: 10.1016/j.jaci.2017.02.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
66 Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, Amoedo M, Pires C. Rituximab use in adult glomerulopathies and its rationale. J Bras Nefrol. 2020;42:77-93. [PMID: 31904761 DOI: 10.1590/2175-8239-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Zhao F, Afonso S, Lindner S, Hartmann A, Löschmann I, Nilsson B, Ekdahl KN, Weber LT, Habbig S, Schalk G, Kirschfink M, Zipfel PF, Skerka C. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases. Front Immunol 2019;10:1030. [PMID: 31214159 DOI: 10.3389/fimmu.2019.01030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
68 Mathur M, Sharma S, Prasad D, Garsa R, Singh AP, Kumar R, Beniwal P, Agarwal D, Malhotra V. Incidence and profile of C3 Glomerulopathy: A single center study. Indian J Nephrol 2015;25:8-11. [PMID: 25684865 DOI: 10.4103/0971-4065.136889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
69 Shimizu Y, Wakabayashi K, Iwasaki H, Kishida C, Seki S, Okuma T, Iwakami N, Iwasawa T, Maekawa H, Tomino Y, Wada R, Suzuki Y. Immunotactoid Glomerulopathy with Nontuberculous Mycobacterial Infection: A Novel Association. Case Rep Nephrol Dial 2021;11:136-46. [PMID: 34250031 DOI: 10.1159/000515583] [Reference Citation Analysis]
70 Paul EA, Guttenberg M, Kaplan P, Watkins D, Rosenblatt DS, Treat JR, Kaplan BS. Atypical glomerulopathy associated with the cblE inborn error of vitamin B₁₂ metabolism. Pediatr Nephrol 2013;28:1135-9. [PMID: 23503767 DOI: 10.1007/s00467-013-2443-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
71 Hagemann JH, Haegele H, Müller S, Anders HJ. Danger control programs cause tissue injury and remodeling. Int J Mol Sci 2013;14:11319-46. [PMID: 23759985 DOI: 10.3390/ijms140611319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
72 Grøndahl C, Rittig S, Povlsen JV, Kamperis K. Protracted Clinical Course of Postinfectious Glomerulonephritis in a Previously Healthy Child. Case Rep Nephrol Dial 2016;6:70-5. [PMID: 27226969 DOI: 10.1159/000445678] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Gambella A, Barreca A, Biancone L, Roccatello D, Peruzzi L, Besso L, Licata C, Attanasio A, Papotti M, Cassoni P. Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service. Biomolecules 2022;12:298. [DOI: 10.3390/biom12020298] [Reference Citation Analysis]
74 Tsuji K, Arai H, Furusu A, Torigoe K, Tokuyama A, Muraya Y, Nakashima M, Taguchi T, Obata Y, Nishino T, Kohno S. A case of membranoproliferative glomerulonephritis and AA amyloidosis complicated with pulmonary nontuberculous mycobacterial infection. CEN Case Rep 2015;4:24-30. [PMID: 28509264 DOI: 10.1007/s13730-014-0134-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
75 Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology 2016;71:131-42. [DOI: 10.1016/j.molimm.2016.01.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
76 Frangou E, Varnavidou-Nicolaidou A, Petousis P, Soloukides A, Theophanous E, Savva I, Michael N, Toumasi E, Georgiou D, Stylianou G, Mean R, Anastasiadou N, Athanasiou Y, Zavros M, Kyriacou K, Deltas C, Hadjianastassiou V. Clinical course and outcome after kidney transplantation in patients with C3 glomerulonephritis due to CFHR5 nephropathy. Nephrol Dial Transplant 2019;34:1780-8. [PMID: 30844074 DOI: 10.1093/ndt/gfz021] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Yurova VA, Bobrova LA, Kozlovskaya NL, Korotchaeva YV, Serova AG, Kozlov LV, Andina SS, Demyanova KA, Kuchieva AM, Roshchupkina SV. [Changes in the complement system in membranoproliferative glomerulonephritis]. Ter Arkh 2017;89:69-77. [PMID: 28745692 DOI: 10.17116/terarkh201789669-77] [Reference Citation Analysis]
78 Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014;85:450-6. [PMID: 24067430 DOI: 10.1038/ki.2013.340] [Cited by in Crossref: 107] [Cited by in F6Publishing: 91] [Article Influence: 11.9] [Reference Citation Analysis]
79 Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-bacchi V, Sellier-leclerc AL. C3 glomerulopathy and eculizumab: a report on four paediatric cases. Pediatr Nephrol 2017;32:1023-8. [DOI: 10.1007/s00467-017-3619-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
80 Pinho A, Ferreira G, Mota C. Successful management of a patient with a C3 Glomerulonephritis and crescentic pattern: a case report. BMC Res Notes 2014;7:792. [PMID: 25380644 DOI: 10.1186/1756-0500-7-792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
81 Thomas S, Ranganathan D, Francis L, Madhan K, John GT. Current concepts in C3 glomerulopathy. Indian J Nephrol. 2014;24:339-348. [PMID: 25484526 DOI: 10.4103/0971-4065.134089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
82 Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney International 2014;86:905-14. [DOI: 10.1038/ki.2014.49] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 8.9] [Reference Citation Analysis]
83 Bomback AS, Markowitz GS, Appel GB. Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways. Kidney Int Rep 2016;1:148-55. [PMID: 29142924 DOI: 10.1016/j.ekir.2016.06.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
84 Cabezas-Falcon S, Norbury AJ, Hulme-Jones J, Klebe S, Adamson P, Rudd PA, Mahalingam S, Ong LC, Alonso S, Gordon DL, Carr JM. Changes in complement alternative pathway components, factor B and factor H during dengue virus infection in the AG129 mouse. J Gen Virol 2021;102. [PMID: 33410734 DOI: 10.1099/jgv.0.001547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Cianciolo RE, Jennette JC. Glomerulonephritis in Animal Models and Human Medicine: Discovery, Pathogenesis, and Diagnostics. Toxicol Pathol 2018;46:898-903. [PMID: 30278837 DOI: 10.1177/0192623318800714] [Reference Citation Analysis]
86 Lavrador V, Correia F, Sampaio R, Cândido C, Sameiro-Faria M, Marques L, Mota C. Membranoproliferative glomerulonephritis and x-linked agammaglobulinemia: an uncommon association. Case Rep Pediatr 2014;2014:480947. [PMID: 24716070 DOI: 10.1155/2014/480947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Bajwa R, DePalma JA, Khan T, Cheema A, Kalathil SA, Hossain MA, Haroon A, Madhurima A, Zheng M, Nayer A, Asif A. C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction. Case Rep Nephrol Dial 2018;8:25-34. [PMID: 29594148 DOI: 10.1159/000486848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]